Pfizer fights for Viagra patent

Share this article:

Still bruised from last week's Celebrex patent decision, Pfizer is back in the courts trying to keep a generic of its ED drug from hitting the markets before its patent expires in 2019, Bloomberg reports.

The company in this battle is India's Torrent Pharmaceuticals, which is seeking to tap into Pfizer's $1.88 billion business.

Bloomberg notes that Torrent is not the first generics maker that it's taken to court over Viagra, and that the company came to an agreement with Teva which would allow the Israel-based pharmaceutical company to manufacture generic Viagra in the US in 2017 “or earlier under certain circumstances.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.